The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono
Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma.
 
Nima Almassi
No Relationships to Disclose
 
Eugene J. Pietzak
Consulting or Advisory Role - Merck
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Second Science; Urogen pharma (I)
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Nikolaus Schultz
No Relationships to Disclose
 
Guido Dalbagni
No Relationships to Disclose
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics
Research Funding - Agensys (Inst); Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Gopa Iyer
Consulting or Advisory Role - Bayer
 
David B. Solit
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA